- Home
- XLO vs RNXT Comparison
XLO vs RNXT Comparison
Compare XLO & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XLO
- RNXT
- Stock Information
- Founded
- XLO 2016
- RNXT 2012
- Country
- XLO United States
- RNXT United States
- Employees
- XLO N/A
- RNXT N/A
- Industry
- XLO Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- XLO Health Care
- RNXT Health Care
- Exchange
- XLO Nasdaq
- RNXT Nasdaq
- Market Cap
- XLO 41.8M
- RNXT 35.2M
- IPO Year
- XLO 2021
- RNXT 2021
- Fundamental
- Price
- XLO $0.75
- RNXT $0.84
- Analyst Decision
- XLO Buy
- RNXT Strong Buy
- Analyst Count
- XLO 1
- RNXT 2
- Target Price
- XLO $2.00
- RNXT $7.75
- AVG Volume (30 Days)
- XLO 996.7K
- RNXT 401.0K
- Earning Date
- XLO 11-13-2025
- RNXT 11-13-2025
- Dividend Yield
- XLO N/A
- RNXT N/A
- EPS Growth
- XLO N/A
- RNXT N/A
- EPS
- XLO N/A
- RNXT N/A
- Revenue
- XLO $31,804,000.00
- RNXT $928,000.00
- Revenue This Year
- XLO $519.70
- RNXT $2,895.35
- Revenue Next Year
- XLO $44.57
- RNXT $313.04
- P/E Ratio
- XLO N/A
- RNXT N/A
- Revenue Growth
- XLO 588.40
- RNXT N/A
- 52 Week Low
- XLO $0.62
- RNXT $0.70
- 52 Week High
- XLO $1.70
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- XLO 46.63
- RNXT 42.66
- Support Level
- XLO $0.73
- RNXT $0.78
- Resistance Level
- XLO $0.81
- RNXT $0.83
- Average True Range (ATR)
- XLO 0.06
- RNXT 0.08
- MACD
- XLO -0.00
- RNXT -0.01
- Stochastic Oscillator
- XLO 51.26
- RNXT 38.32
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.